AFF1 and liver disorder: For example, (+)-chelidonine, identified in our docking screen as a top candidate, has demonstrated anti-inflammatory and anti-proliferative activities in previous cell-based models, but its affinity for AFF1 and efficacy in liver disease contexts are untested.